Attached files
| file | filename |
|---|---|
| EX-12 - COMPUTATION OF EARNINGS TO FIXED CHARGES - BRISTOL MYERS SQUIBB CO | exhibit12ratioofearningsto.htm |
| EX-32.B - EXHIBIT 32.B - BRISTOL MYERS SQUIBB CO | bmyex32b_20170630.htm |
| EX-31.B - EXHIBIT 31.B - BRISTOL MYERS SQUIBB CO | bmyex31b_20170630.htm |
| EX-31.A - EXHIBIT 31.A - BRISTOL MYERS SQUIBB CO | bmyex31a_20170630.htm |
| EX-10.B - AMENDMENT TO 2012 CREDIT AGREEMENT - BRISTOL MYERS SQUIBB CO | bmyex10b2017amendmentfor20.htm |
| EX-10.A - AMENDMENT TO 2011 CREDIT AGREEMENT - BRISTOL MYERS SQUIBB CO | bmyex10a2017amendmentandwa.htm |
| 10-Q - FORM 10-Q - BRISTOL MYERS SQUIBB CO | bmy-20170630x10q.htm |
EXHIBIT 32a.
Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (the Report), as filed with the Securities and Exchange Commission on July 27, 2017, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ Giovanni Caforio |
Giovanni Caforio Chief Executive Officer |
July 27, 2017
E-32-1